Literature DB >> 26836707

Formulation, physicochemical characterization and stability study of lithium-loaded microemulsion system.

Abdelkader Mouri1, Philippe Legrand2, Abdeslam El Ghzaoui3, Christophe Dorandeu4, Jean Claude Maurel5, Jean-Marie Devoisselle4.   

Abstract

Lithium biocompatible microemulsion based on Peceol(®), lecithin, ethanol and water was studied in attempt to identify the optimal compositions in term of drug content, physicochemical properties and stability. Lithium solubilization in microemulsion was found to be compatible with a drug-surfactant binding model. Lithium ions were predominantly solubilized within lecithin head group altering significantly the interfacial properties of the system. Pseudo-ternary phase diagrams of drug free and drug loaded microemulsions were built at constant ethanol/lecithin weight ratio (40/60). Lithium loaded microemulsion has totally disappeared in the Peceol(®) rich part of phase diagram; critical fractions of lecithin and ethanol were required for the formation of stable microemulsion. The effect of lithium concentration on the properties and physical stability of microemulsions were studied using microscopy, Karl Fischer titrations, rheology analyses, conductivity measurements and centrifugation tests. The investigated microemulsions were found to be stable under accelerated storage conditions. The systems exhibited low viscosity and behaved as Newtonian fluid and no structural transition was shown.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Binding process; Lecithin; Lithium; Phase diagram; W/O microemulsion

Mesh:

Substances:

Year:  2016        PMID: 26836707     DOI: 10.1016/j.ijpharm.2016.01.072

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

Review 1.  The Crosstalk Between Pathological Tau Phosphorylation and Mitochondrial Dysfunction as a Key to Understanding and Treating Alzheimer's Disease.

Authors:  Sanjib Guha; Gail V W Johnson; Keith Nehrke
Journal:  Mol Neurobiol       Date:  2020-08-26       Impact factor: 5.590

2.  Lithium as a disease-modifying agent for prion diseases.

Authors:  A Relaño-Ginés; S Lehmann; E Brillaud; M Belondrade; D Casanova; C Hamela; C Vincent; S Poupeau; J Sarniguet; T Alvarez; J D Arnaud; J C Maurel; C Crozet
Journal:  Transl Psychiatry       Date:  2018-08-22       Impact factor: 6.222

3.  Eprinomectin nanoemulgel for transdermal delivery against endoparasites and ectoparasites: preparation, in vitro and in vivo evaluation.

Authors:  Yujuan Mao; Xiaolan Chen; Bohui Xu; Yan Shen; Zixuan Ye; Birendra Chaurasiya; Li Liu; Yi Li; Xiaoling Xing; Daquan Chen
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

4.  BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology.

Authors:  E N Wilson; S Do Carmo; M F Iulita; H Hall; A Ducatenzeiler; A R Marks; S Allard; D T Jia; J Windheim; A C Cuello
Journal:  Transl Psychiatry       Date:  2017-08-01       Impact factor: 6.222

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.